Company Description

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α.

Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.

Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis.

CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

CervoMed Inc.

Country	United States
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	15
CEO	John Alam

Contact Details

Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States
Phone	617 744 4400
Website	cervomed.com

Stock Details

Ticker Symbol	CRVO
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001053691
CUSIP Number	15713L109
ISIN Number	US15713L1098
Employer ID	30-0645032
SIC Code	2834

Key Executives

Name	Position
Dr. John J. Alam M.D.	Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D.	Co-Founder and Director
Kelly Blackburn M.H.A.	Executive Vice President of Clinical Development
Dr. Mark A. De Rosch Ph.D.	Executive Vice President of Regulatory, Government Affairs and Program Management
Dr. Claudia Ordonez M.D.	Senior Vice President of Medical Science

Latest SEC Filings

Date	Type	Title
Mar 23, 2026	8-K	Current Report
Mar 19, 2026	8-K	Current Report
Mar 17, 2026	8-K	Current Report
Mar 13, 2026	10-K	Annual Report
Mar 4, 2026	8-K	Current Report
Feb 18, 2026	8-K	Current Report
Feb 11, 2026	SCHEDULE 13G	Filing
Jan 8, 2026	8-K	Current Report
Dec 5, 2025	8-K	Current Report
Nov 10, 2025	8-K	Current Report

View All SEC Filings